



When Should You Suspect Tuberculosis (TB)?

TB is a disease caused by *Mycobacterium tuberculosis*. TB disease should be suspected in persons who have the following symptoms:

- Unexplained weight loss
- Loss of appetite
- Night sweats
- Fever
- Fatigue

If TB disease is in the lungs (pulmonary), symptoms may include:

- Coughing for ≥ 3 weeks
- Hemoptysis (coughing up blood)
- Chest pain

If TB disease is in other parts of the body (extrapulmonary), symptoms will depend on the area affected.

How Do You Evaluate Persons Suspected of Having TB Disease?

A complete medical evaluation for TB includes the following:

1. Medical History

Clinicians should ask about the patient's history of TB exposure, infection, or disease. It is also important to consider demographic factors (e.g., country of origin, age, ethnic or racial group, occupation) that may increase the patient's risk for exposure to TB or to drug-resistant TB. Also, clinicians should determine whether the patient

2. Physical Examination

A physical exam can provide valuable information about the patient's overall condition and other factors that may affect how TB is treated, such as HIV infection or other illnesses.

3. Test for TB Infection

The [Mantoux tuberculin skin test \(TST\)](#) or the [TB blood test \(Interferon Gamma Release Assay \(IGRA\)\)](#) can be used to test for *M. tuberculosis* infection. Additional tests are required to confirm TB disease. The Mantoux tuberculin skin test is performed by injecting a small amount of fluid called tuberculin into the skin in the lower part of the arm. The test is read within 48 to 72 hours by a trained health care worker, who looks for a reaction (induration) on the arm.

Testing for TB in People with a [BCG](#)

People who have had a previous BCG shot may receive a TST. In some people, the BCG shot may cause a positive TST when they are not infected with TB bacteria. If a TST is positive, additional tests are needed.

The TB blood test (IGRA) measures the patient's immune system reaction to *M. tuberculosis*. Blood tests to detect TB infection, unlike the TST, are not affected by prior BCG vaccination and are less likely to give a false-positive result

Two IGRAs are approved by the U.S. Food and Drug Administration (FDA) and are available in the United States:

- 1) QuantiFERON®-TB Gold In-Tube test (QFT-GIT)
- 2) T-SPOT®.TB test (T-Spot)

Healthier Together



4. Chest Radiograph

A posterior-anterior chest radiograph is used to detect chest abnormalities. Lesions may appear anywhere in the lungs and may differ in size, shape, density, and cavitation. These abnormalities may suggest TB, but cannot be used to definitively diagnose TB. However, a chest radiograph may be used to rule out the possibility of pulmonary TB in a person who has had a positive reaction to a TST or TB blood test and no symptoms of disease.

5. Diagnostic Microbiology

The presence of acid-fast-bacilli (AFB) on a **sputum** (other specimen) **smear** or **NAAT** often indicates TB disease. [NAA testing](#) should be performed on at least one respiratory specimen from each patient with signs and symptoms of pulmonary TB for whom a diagnosis of TB is being considered but has not yet been established, and for whom the test result would alter case management or TB control activities. Acid-fast microscopy is easy and quick, but it does not confirm a diagnosis of TB because some acid-fast-bacilli are not *M. tuberculosis*. Therefore, a **culture** is done on all initial samples to confirm the diagnosis. (However, a positive culture is not always necessary to begin or continue treatment for TB.) A positive culture for *M. tuberculosis* confirms the diagnosis of TB disease. Culture examinations should be completed on all specimens, regardless of AFB smear results. Laboratories should report positive results on smears and cultures within 24 hours by telephone or fax to the primary health care provider and to the state or local TB control program

6. Drug Resistance

For all patients, the initial *M. tuberculosis* isolate should be tested for drug resistance. It is crucial to identify drug resistance as early as possible to ensure effective treatment. Drug susceptibility patterns should be repeated for patients who do

not respond adequately to treatment or who have positive culture results despite 3 months of therapy. Susceptibility results from laboratories should be promptly reported to the primary health care provider and the state or local TB control program.

For Reporting, Questions and concerns:

Contact Southwest District Health Epidemiology program

- Phone – 208 455 5442
- Fax - 208 455 5350

Additional Information

1. American Thoracic Society (ATS) and CDC. Diagnostic standards and classification of tuberculosis in adults and children. (PDF) *Am J Respir Crit Care Med* 2000; 161. <http://ajrccm.atsjournals.org/cgi/content/full/161/4/1376>
2. ATS, CDC, and Infectious Diseases Society of America. Treatment of tuberculosis. *MMWR* 2003; 52 (No. RR-11). <http://www.cdc.gov/mmwr/PDF/rr/rr5211.pdf>
3. Centers for Disease Control and Prevention. Guidelines for the investigation of contacts of persons with infectious tuberculosis and Guidelines for using the QuantiFERON®-TB Gold test for detecting Mycobacterium tuberculosis infection, United States. *MMWR* 2005; 54 (No. RR-15). <http://www.cdc.gov/mmwr/pdf/rr/rr5415.pdf>
4. Updated Guidelines for the Use of Nucleic Acid Amplification Tests in the Diagnosis of Tuberculosis. *MMWR* 2009;58(1). http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5801a3.htm?scid=mm5801a3_e

Healthier Together

13307 Miami Lane ● Caldwell, ID 83607 ● (208) 455-5300 ● FAX (208) 454-7722